Updated on 31 May 2012
Dr Eitan Konstantino, CEO and co-founder, TriReme Medical
TriReme Medical, a US-based start-up medical devices company dedicated to the development and manufacturing of innovative devices for the treatment of complex vascular disease, recently opened its regional research and development, global sales and manufacturing center in Singapore. The Singapore facility focuses on coronary and peripheral products, while also producing the company's innovative product, Chocolate PTA Balloon Catheter, the first Singaporean interventional device approved by the US Food and Drug Administration (FDA).
TriReme is focusing more on Singapore than other countries of the region, such as China and Vietnam, to develop it as their hub for Asia manufacturing and operations. In the last one year, the company has invested millions of dollars in Asia and is looking forward to expanding its operations in the region.
In an interview with BioSpectrum, Dr Eitan Konstantino, CEO and co-founder, TriReme Medical, shares company strategies to penetrate Asia.
Tell us about the operations of TriReme in Asia.
Dr Konstantino: We have always had the Asian opportunity in mind. We were intrigued by the fast-growing markets in the region compared to the limited growth of Europe and the US. We are based in Hong Kong, Malaysia, Thailand and are working with Century Medical in Japan, which is our distributor. We also have high interest in China and are in the process of getting our products registered with the SFDA. The Singapore hub is equipped to manufacture our products and also manage subcontractors in Singapore, Europe and the US.